Working between IP and business development, Eline supports researchers in protecting and developing their ideas.

When a drug screen in organoids pointed us towards a new drug combination against a subtype of colorectal cancer, we wanted to test it in patients. The journey from lab to clinic took ten years, three disciplines, and a risk-tolerant funding model. It led us to an unexpected destination.

Oncode Institute today announces the launch of the Oncology Bridge Fund II (OBF II), in collaboration with Ligase BioPartners, building on their established partnership in the first Oncology Bridge Fund (OBF I). This fund signals a next step, in scaling up Oncode Institute’s valorisation efforts, accelerating  translation of breakthrough cancer research into societal, clinical and patient impact. 

Leadership transition at Oncode Accelerator strengthens the alignment with Oncode Institute as Bertholt Leeftink takes on the role of CEO and Chair of the Board of Directors.

On 26 March, Oncode Institute will take part in a live BiotechNews interview during Innovation for Health in Utrecht. The discussion will bring together Bertholt Leeftink and Shobhit Dhawan to reflect on how strong oncology research can translate into real impact for patients.

The ILLUMINE team will explore a largely unseen layer of cancer biology. Their work aims to understand how these hidden proteins appear and how they might help reveal new treatment possibilities.

Four Oncode Investigators have been awarded highly competitive Cancer Grand Challenges grants. This exceptional international recognition highlights the strength of Dutch cancer research and unlocks substantial new funding to accelerate fundamental discoveries toward tangible impact for patients.

Meet Tessy and see how she helps researchers explore where their discoveries can lead.

Four Oncode Investigators have been awarded highly competitive Cancer Grand Challenges grants. This exceptional international recognition highlights the strength of Dutch cancer research and unlocks substantial new funding to accelerate fundamental discoveries toward tangible impact for patients.

Meet Chung, our Financial Controller who keeps our financial processes clear and consistent.

A €1.5 million Vici grant will support new research into epigenetic plasticity in prostate cancer, aiming to uncover mechanisms that drive disease progression and open the door to more precise and durable treatment options.

Meet Anoushka and see how she helps ideas, people and programmes come together.

Oncode Institute spin-off Omivera, built around the CellEKT chemical proteomics platform, has secured a seed investment from UNIIQ, an investment fund focused on the proof-of-concept phase, aiming to bring innovations to the market faster. 

Cancer research often advances through ideas that are complex, and require sustained effort over time - driven by people with a strong sense of purpose. In this interview, Madelon Maurice, professor of molecular cell biology at University Medical Centre Utrecht (UMC Utrecht) and Oncode Institute investigator, and Maureen Spit, Vice President of Research at Laigo Bio, reflect on what motivates them as scientists and why they chose to focus on one of the most persistent challenges in oncology: how to target cancer-driving proteins that remain beyond the reach of current therapies.

The Alpe d’HuZes/KWF Fund will invest €4.5 million in Oncode Institute over the next two years. Made possible by the participants of Alpe d’HuZes, this funding accelerates innovative cancer research and enables promising ideas to more quickly develop into applications for patients. The investment supports multiple innovative research projects and aligns with the Alpe d’HuZes research themes: understanding, detection, and cure.

A novel cancer treatment strategy that enables the targeted degradation of membrane proteins has received funding from the highly competitive European Innovation Council Pathfinder programme. The OutMARCH project aims to make previously “undruggable” cancer proteins accessible, potentially offering new ways to overcome resistance to existing therapies.